News

Matricelf is happy to announce that Dr. Eckhard von Keutz is joining our Scientific Advisory Board.
Dr Von Keutz is an expert and consultant for pharma research and development with special focus on preclinical and early clinical development.
Until recently Dr Von Keutz was the Senior Vice President and Head of Translational Sciences at Bayer AG, Pharmaceuticals where he directed the global activities of all preclinical and early clinical development functions. Dr Von Keutz is the Chairman of the Advisory Board of the Fraunhofer Institute of Toxicology and Experimental Medicine (Hannover, Germany); Member of the Executive Council at Center of Healthcare Innovation (US); Member of the Advisory Committee for Pharmacologically Active Substances and Veterinary Drugs of the German Federal Institute for Risk Assessment; Member of the CAAT Advisory Board (Europe); Member of the Industrial Advisory Board (IAB) of the European Organ-on-Chip Society (EUROoCS) and starting today a member of our Scientific advisory board.
We welcome Eckhard to our family and wish us all success in our journey to regenerate the future of medicine.

Matricelf is excited to announce that it won the state finals at the Startup World Cup and will represent Israel in the Startup World Cup Grand Finale in November 2021 in San Francisco.
The Startup World Cup, sponsored by Pegasus Tech Ventures, is the largest startup competition around the world with more then 10,000 applicants from more then 50 regions and a grand prize of 1,000,000 USD.
We are honored to represent Israel and hopefully bring a lot of respect but more important to find the cure for disabled patients with Spinal Cord Injury.

Israeli 3D Printing Tech Hopes to Revolutionize Spinal Cord Injury Treatment

What a great way to end 2020!
We are happy to announce that Matricelf is the winner at the Startup+ competition by Calcalist and Poalim HI-TECH!
Dr Asaf Toker, Matricelf CEO: "it is a small step for the company on its way to help paralyzed patients with spinal cord injury make their own steps".
Matricelf develops a complete autologous neural implant and is working towards a first in human clinical trial during 2023.

Matricelf is happy to announce the appointment of Mr Doron Birger to be the chairman of the board of directors of the company.
Doron serves as the chairman and a director in a variety of technology companies, mainly in medical device companies.
In the past, Doron served as the CEO of Elron (Nasdaq: ELRNF, TASE: ELRN) and as the chairman and director of Given Imaging (previously traded at Nasdaq: GIVN; TASE: GIVN) until it was sold to Covidien (now Medtronic) for approximately USD 1 billion.
Doron is replacing Prof Avishay Braverman who served as the chairman for the last year.
We wish Doron a great journey and lots of successes with us.

Matricelf is excited to welcome MCP Magna Capital Partners to our investors list.

Founded by a group of experienced business owners and close friends, MCP Magna Capital Partners Ltd. invests in bold israeli teams building the future through technology.
MCP invest in seed and series A stage Israeli technology companies across the digital health, medical device, bio/healthcare and enterprise software spaces. MCP proudly invested in Rewalk ($RWLK), Urogen Pharma ($URGN) and Yotpo.

We hope that we will have an amazing journey together while we are regenerating the future of medicine.

Matricelf is delighted to announce that it has been selected as a “One to Watch” for the 2020 Spinoff Prize by Nature Research, part of Springer Nature, and Merck.
Selected from almost 150 entrants by an expert panel of judges, the Spinoff Prize aims to provide visibility and support for academic entrepreneurs and their companies, worldwide.

Yariv Bash is one of the entrepreneurs and founders of SpaceIL that launched the space shuttle “BERESHIT” to the moon.
Yariv is a visionary, an optimistic and an interlocutor.
Yariv is in a wheelchair due to a ski accident.
A few months ago, I heard an interview with him and he said that: “humanity succeeded reaching the space but it still didn’t succeed to bridge two centimeters of injured spinal cord”.
Yarivs’ thoughts are our vision – to engineer those two centimeters of spinal cord gap to enable paralyzed patients due to traumatic Spinal cord Injuries to regain normal functions.
We were honored to host Yariv today at Matricelf office

We Are happy to announce that we received our first approval for a clinical trial in humans to collect Omentum samples for our R&D program.
This is another small step toward our planned first in human clinical trial for spinal Cord Injury.

Big honor to Matricelf!
Prof Dvir, Matricelf CSO, presents the first ever human 3D printed heart to his royal highness Prince Charles, Prince of Wales

When the creative minds that drive Israeli biotechnology company Matricelf started telling people about their plan to create the world’s first 3D printed human heart the common response was that they were talking about the stuff of dreams.

Matricelf is greeting our Chief scientist, Prof Tal Dvir, for being selected as one of the 20 promising Israeli scientists for the new decade

Top 10 Israeli inventions of the last 10 years

Researchers from Tel Aviv University “printed” the world’s first 3D engineered heart using a patient’s own cells and biological materials. Importantly, the breakthrough saw success in printing vasculature, and the heart matched the immunological and cellular properties of the patient.